Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M

Reuters

2025/05/13

Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M

Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535895467"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535895467\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535895467?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535895467","market":"us","top_or_hot":-1,"title":"Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-13 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDLc2GKmQ:1","article_id":"2535895467","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535895467","pubTimestamp":1747080077,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Addit","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","XENE":"Xenon制药"},"translate_title":"Xenon Pharmaceuticals报告2025年第一季度收入飙升至750万美元；净亏损扩大至6500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XENE":0.9,"NDAQ":0.9},"content_text":"Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n    \n\n        Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}